Healthcare perspectives from The Economist Intelligence Unit



Hero Carousel


Bringing healthcare to hard-hit areas in Bangladesh




COVID and Cardiovascular disease

Cardiovascular disease (CVD) is the world’s deadliest family of non-communicable diseases. Since the advent of the covid-19 pandemic, it has become clear that CVD and covid-19 multiply each other’s severity and, ultimately, lethality.

World Immunisation Week: 24th—30th April 2022

Two decades ago, the US Centers for Disease Control and Prevention (CDC) declared vaccinations to be one of the major public health achievements of the twentieth century, placing it first in its top 10 list.

Will the intersection of health, people and planet lead to action?

World Health Day 2022 emphasises the interconnectedness of people and planet health. David Humphreys, global practice leader for health policy, provides insights on translating strong evidence and beliefs into action around the relationship between health, thriving societies and a sustainable world.

Together for mental health: towards a sustainable and scalable model of mental health care in the United Arab Emirates

Good mental health is integral to the functioning, wellbeing and performance of individuals, communities, society, and the economy. Yet, mental health remains one of the most neglected areas of public health. On average, mental health accounts for just 2% of overall health budgets. Access to quality mental health services remains a challenge globally, with barriers including awareness, availability, affordability, and stigma.

Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success

‘Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success’ is a whitepaper, written by Economist Impact, and commissioned by Medtronic in support of the EDB. The report details the current state of the Health and Medical Technologies (MedTech) sector in the Asia Pacific region, identifies the challenges for early-stage start-ups and small and mid-size enterprises (SMEs), and considers steps that can be taken to support this strategically important and growing market. 

Article 2 | Roadmap to resilience: A post pandemic vision of healthcare delivery

While the covid-19 pandemic has shed light on the pre-existing vulnerabilities of health systems worldwide, it has also brought key areas of resilience-building into urgent and sharper focus. Issues such as supply chain shortages, staff burnout and challenges to meet the ongoing surge in healthcare demand were experienced globally, in addition to regional and country-level challenges that have been more unique and contextual. 

Rare paediatric neurological diseases: A focus on Europe

Rare paediatric neurological conditions are debilitating diseases with massive impacts on the day-to-day lives of children and their families. Most rare diseases have neurological symptoms, and about 90% of those affecting children have major neurological effects impacting the ability to achieve key cognitive and physical development milestones.

Mental health at work: From promise to practice

A hidden crisis made visible

Before the pandemic, mental health was often treated as an afterthought to physical health in the support offered by employers. A steady rise in ‘workforce wellness’ programs has clearly been underway in the US, driven by factors including the need to contain healthcare costs and attract and retain talent. Additionally, more progressive companies have recognised the close links between engaged employees and better business outcomes.

Infectious and non-communicable diseases in Asia-Pacific: The need for integrated healthcare

Infectious and non-communicable diseases in Asia-Pacific: The need for integrated healthcare is an Economist Impact report that is sponsored by Roche. The paper analyses the current state of policy and practice regarding infectious and non-communicable diseases in the Asia-Pacific region and advocates ways to better ensure that infectious and non-communicable diseases are tackled synergistically, given their linkages.

Confronting the fragility of medicine supply chains

Confronting the fragility of medicine supply chains is an Economist Impact report, sponsored by LEO Pharma A/S. The white paper examines the complex causes of disruptions in the supply chains for drugs, with a particular focus on their active pharmaceutical ingredients (APIs). Disruption of supply chains was a common feature of the pandemic. Yet, the structural and economic circumstances that helped contribute to these problems were in existence well before covid-19 made its first appearance.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week